免费体验“高时效”国际投行研报“T+0至T+1”“原研报”可至底部下载高盛——药明生物（2269.HK）：2025年下半年初步业绩大概率因“R”业务贡献提升而超预期；关注订单增长及2026年业绩指引翻译精华1. 药明生物发布2025年盈利预喜，全年营收同比增长16.7%，略高于14%-16%的业绩指引；2025年下半年营收118亿元（同比+17.2%），略高于高盛及市场一致预期（均为117亿元），...
Source Link免费体验“高时效”国际投行研报“T+0至T+1”“原研报”可至底部下载高盛——药明生物（2269.HK）：2025年下半年初步业绩大概率因“R”业务贡献提升而超预期；关注订单增长及2026年业绩指引翻译精华1. 药明生物发布2025年盈利预喜，全年营收同比增长16.7%，略高于14%-16%的业绩指引；2025年下半年营收118亿元（同比+17.2%），略高于高盛及市场一致预期（均为117亿元），...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.